Megaloblastic maturation is the morphologic result of any biochemical defect that causes a slowing of DNA synthesis. The hallmark of this megaloblastosis is nuclear-cytoplasmic dissociation; the ...
A compound effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs) has been identified, raising hopes of producing drugs capable of eradicating refractory tumors with low ...
Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis), a CD20-directed cytolytic monoclonal antibody, resulted in a highly significant and clinically ...
For many years, RA was treated primarily with nonsteroidal anti-inflammatory drugs (NSAIDs). While NSAIDS, including the newer generation cyclo-oxygenase (COX-2) inhibitors, decrease inflammation and ...
One of French drugmaker Sanofi’s top-selling products could face some significant competition after the presentations of two Phase III studies at a multiple sclerosis conference of drugs shown to have ...
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Aubagio (teriflunomide; Genzyme) that includes revisions to the Contraindications, Warnings and ...
The usual Aubagio (teriflunomide) dosage is 7 or 14 milligrams (mg) taken once per day. Your dosage might vary based on factors like how severe your condition is and other medications you take.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolves rapidly under the pressure of host immunity, as evidenced by waves of emerging variants despite effective vaccinations, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback